MDxHealth SA (NASDAQ:MDXH) Given Consensus Rating of “Hold” by Brokerages

Shares of MDxHealth SA (NASDAQ:MDXH) have earned a consensus recommendation of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $2.8333.

A number of brokerages recently issued reports on MDXH. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Lake Street Capital set a $3.00 price target on MDxHealth and gave the company a “buy” rating in a report on Friday. BTIG Research reduced their price target on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen raised MDxHealth to a “sell” rating in a research note on Saturday. Finally, TD Cowen restated a “buy” rating and set a $1.50 price objective (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th.

Hedge Funds Weigh In On MDxHealth

Large investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. raised its stake in MDxHealth by 7.1% during the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock worth $3,396,000 after purchasing an additional 97,500 shares during the period. Kennedy Capital Management LLC purchased a new stake in shares of MDxHealth during the 3rd quarter valued at $1,826,000. FreeGulliver LLC grew its stake in shares of MDxHealth by 25.7% during the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after buying an additional 65,000 shares during the period. Renaissance Technologies LLC increased its holdings in shares of MDxHealth by 21.8% during the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after buying an additional 54,600 shares during the last quarter. Finally, Mink Brook Asset Management LLC increased its holdings in shares of MDxHealth by 64.9% during the 4th quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after buying an additional 103,686 shares during the last quarter.

MDxHealth Price Performance

MDxHealth stock opened at $0.81 on Friday. MDxHealth has a 12-month low of $0.40 and a 12-month high of $5.33. The stock has a market capitalization of $40.00 million, a P/E ratio of -1.12 and a beta of 1.42. The firm’s 50-day moving average is $0.47 and its two-hundred day moving average is $1.78.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million. As a group, analysts forecast that MDxHealth will post -0.6 EPS for the current year.

MDxHealth News Roundup

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: MDxHealth reported second-quarter revenue of $27.2 million, up 16% year over year and above the approximately $26.1 million analyst estimate. The company’s $0.18 per-share loss was slightly better than the $0.19 consensus cited by MarketBeat, although another estimate tracked by Zacks showed a larger expected loss of $0.12. MDxHealth Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed an optimistic FY 2026 revenue outlook of $110 million to $115 million, well above the roughly $98.8 million consensus estimate. This suggests management expects continued commercial momentum. MDxHealth Earnings Report
• Positive Sentiment: Management discussed the results and outlook during its second-quarter earnings call, giving investors additional detail on the company’s operating performance and growth plans. MDxHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Trading in MDXH was temporarily paused several times under the exchange’s Limit Up-Limit Down mechanism. The halts do not represent a fundamental company announcement, but they underscore unusually high volatility and speculative trading activity.
• Negative Sentiment: MDxHealth agreed to raise $20 million through a direct share offering. The added funding may support operations and growth, but issuing new shares can dilute existing shareholders and may be contributing to the sharp price swings. MDxHealth Raises $20 Million in Direct Share Offering

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.